| MRSH |
Report |
Consolidated underlying revenue growth |
BEAT |
pred ~3.7% vs. cons 3.6% |
MEDIUM |
| MRSH |
Report |
Risk & Insurance underlying revenue growth |
BEAT |
pred ~3.2% vs. cons 3.1% |
MEDIUM |
| MRSH |
Report |
Adjusted operating margin |
IN-LINE |
pred ~29.4% vs. cons 29.26% |
MEDIUM |
| MRSH |
Guide |
Underlying revenue growth outlook |
BETTER |
guide ~4.0% vs. cons 3.8% (FY2026) |
MEDIUM |
| MRSH |
Guide |
Adjusted operating margin expansion |
BETTER |
guide ~20 bps vs. cons 15 bps (FY2026) |
LOW |
| MRSH |
Guide |
Fiduciary interest income |
LOWER |
guide ~$75M vs. cons $78M (2026Q3) |
MEDIUM |
| MRSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| MRSH |
Return |
5-day cumulative residual |
+0.6% (FADE) |
The initial relief from pred ~3.7% underlying growth versus 3.6% consensus should fade as guide ~$75M of Q3 fiduciary interest income versus $78M consensus and continued Guy Carpenter pricing pressure limit out-period estimate revisions. |
MEDIUM |